- Open
- 11.38
- High
- 11.75
- Low
- 11.00
- Close
- 11.40
- Change
- -0.38 (-3.30%)
- Volume
- 436,980
| 30 Sept 2026 | 07:00:06 | Unaudited interim results |
| 5 Aug 2026 | 11:57:42 | Holding(s) in Company |
| 28 Jul 2026 | 07:00:04 | H1-26 Trading Update |
| 23 Jul 2026 | 07:00:06 | MicroBlate™ Flex exceeds 100 clinical cases |
| 18 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 11 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 3 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Creo Medical Group PLC develops and commercializes advanced energy medical devices for minimally invasive endoscopic procedures, primarily targeting cancer and pre-cancer indications in the gastrointestinal tract, pancreas, liver, and lung. The company operates through its proprietary CROMA energy platform, offering products such as Speedboat Notch and SpydrBlade Flex, which enhance treatment efficacy and patient outcomes. Creo serves healthcare providers globally, focusing on improving surgical techniques and reducing procedure times and costs. The company collaborates with other sectors, including robotic surgery, to expand its market reach and product applications.
| 30 Sept 2026 | 07:00:06 | Unaudited interim results |
| 5 Aug 2026 | 11:57:42 | Holding(s) in Company |
| 28 Jul 2026 | 07:00:04 | H1-26 Trading Update |
| 23 Jul 2026 | 07:00:06 | MicroBlate™ Flex exceeds 100 clinical cases |
| 18 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 11 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 3 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Creo Medical Group PLC develops and commercializes advanced energy medical devices for minimally invasive endoscopic procedures, primarily targeting cancer and pre-cancer indications in the gastrointestinal tract, pancreas, liver, and lung. The company operates through its proprietary CROMA energy platform, offering products such as Speedboat Notch and SpydrBlade Flex, which enhance treatment efficacy and patient outcomes. Creo serves healthcare providers globally, focusing on improving surgical techniques and reducing procedure times and costs. The company collaborates with other sectors, including robotic surgery, to expand its market reach and product applications.
| 6 Jul 2026 |
| 14:00:01 |
| Award of Shares under Share Incentive Plan |
| 26 Jun 2026 |
| Week Ahead: Sainsbury’s, AB Foods, Currys, Focusrite |
| 22 May 2026 | Small cap wrap: American Resources, Ceres Power, Creo Medical Group... |
| 22 May 2026 | AIM movers: Creo Medical raises cash for growth and FIH special dividend |
| 22 May 2026 | Creo Medical Group sees 50% surge in year-on-year revenues |
| 22 May 2026 | Creo Medical shares surge 27% on proposed sale of remaining European stake |
| 22 May 2026 | Creo Medical Group to raise £5.5m and advance partial divestment |
| 6 Jul 2026 |
| 14:00:01 |
| Award of Shares under Share Incentive Plan |
| 26 Jun 2026 |
| Week Ahead: Sainsbury’s, AB Foods, Currys, Focusrite |
| 22 May 2026 | Small cap wrap: American Resources, Ceres Power, Creo Medical Group... |
| 22 May 2026 | AIM movers: Creo Medical raises cash for growth and FIH special dividend |
| 22 May 2026 | Creo Medical Group sees 50% surge in year-on-year revenues |
| 22 May 2026 | Creo Medical shares surge 27% on proposed sale of remaining European stake |
| 22 May 2026 | Creo Medical Group to raise £5.5m and advance partial divestment |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.68bn | +0.0% | |
| £1.74bn | -0.1% | |
| £625m | +0.3% | |
| £276m | +0.0% | |
CREOCreo Medical Group PLC | £51m | +0.0% |
| £3m | -0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.68bn | +0.0% | |
| £1.74bn | -0.1% | |
| £625m | +0.3% | |
| £276m | +0.0% | |
CREOCreo Medical Group PLC | £51m | +0.0% |
| £3m | -0.4% |